4505 EMPEROR BOULEVARD, DURHAM, NC
Reports Full Year 2025 Financial Results and Provides Business Update
Material Contracts, Completing Asset Acquisition or Sale, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Reg. FD
Amended material disclosure
Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
BioCryst Pharmaceuticals Increases ORLADEYO® Wholesale Acquisition Cost
FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
Director Retirement - Nancy J. Hutson Steps Down from BioCryst Board
Receives Early Termination of HSR Waiting Period for Acquisition
FY 2024
Q3
Q2
Q1
FY 2023
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-4/A
Prospectus Filed Pursuant to Rule 425
S-4
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence
SEC Staff Correspondence